Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]), the Cambridge, MA-based developer of RNA interference drugs, said today it has filed a legal response and counterclaim against Vancouver, BC-based Tekmira Pharmaceuticals, which accused Alnylam last month of misappropriating trade secrets. Alnylam president Barry Greene said in a statement that the company plans to “fully defend itself.”
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
